Mode
Text Size
Log in / Sign up
N/A N=144 Randomized Single-blind Treatment

Prospective Study of an Investigational Toric Soft Contact Lens

Myopia · Astigmatism · Refractive Error

Enrolled (actual)
144
Serious AEs
0.0%
Results posted
Oct 2013
Primary outcome: Primary: Contact Lens-Corrected Distance Monocular Snellen Visual Acuity (VA) (20/30 or Better) — 98.9; 98.9; 98.9; 97.8 Percentage of eyes

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Nelfilcon A toric contact lenses (with comfort additives) (Device); Nelfilcon A toric contact lenses (Device)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
CIBA VISION
Primary completion
Apr 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Contact Lens-Corrected Distance Monocular Snellen Visual Acuity (VA) (20/30 or Better)
98.9; 98.9; 98.9; 97.8; 98.9; 97.8
SECONDARY
Subjective Rating of Insertion Comfort
8.9; 9.0; 9.0; 9.0; 9.0; 9.1
SECONDARY
Subjective Rating of End of Day Comfort
7.2; 7.6; 7.6; 7.9; 7.6; 8.2
SECONDARY
Subjective Rating of Overall Comfort
8.1; 8.7; 8.3; 8.7; 8.4; 8.8
SECONDARY
Subjective Rating of End of Day Dryness
7.1; 7.1; 7.2; 7.6; 7.3; 7.9
SECONDARY
Subjective Rating of Overall Vision
8.6; 8.9; 8.7; 8.8; 8.8; 8.9
SECONDARY
Subjective Rating of Overall Handling
9.0; 9.0; 8.8; 8.7; 9.0; 8.8
SECONDARY
Lens Centration (Centered, Slight Decentration)
97.8; 98.9; 100; 100; 100; 100
SECONDARY
Lens Fit (Optimal, Acceptably Loose, Acceptably Tight)
100; 100; 100; 100; 100; 100
SECONDARY
Front Surface Wettability (None, Very Slight)
99.4; 100; 92.2; 97.8; 94.9; 95.6
SECONDARY
Front Surface Deposits (None, Very Slight)
100; 100; 96.1; 100; 98.3; 100
SECONDARY
Back Surface Debris/Deposits (None, Very Slight)
100; 100; 98.9; 100; 100; 100

Summary

The purpose of this study was to demonstrate substantial equivalence of an investigational toric soft contact lens to the commercially available Focus® DAILIES® Toric soft contact lens when worn in a daily wear, daily disposable mode for three months.

Eligibility Criteria

Inclusion Criteria

  • Sign Informed Consent document. If under legal age of consent, legally authorized representative must sign Informed Consent document and participant must sign Assent document.
  • Normal eyes not using any ocular medications that would contraindicate lens wear.
  • Willing and able to wear toric contact lenses in both eyes within the available range of powers for this trial.
  • Spectacle cylinder prescription between 0.50 and 2.00 diopters.
  • Best spectacle corrected visual acuity 20/25 (Snellen) or better in each eye at distance.
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

  • Anterior segment infection, inflammation, or abnormality.
  • Any active anterior segment or systemic disease that would contraindicate contact lens wear.
  • Use of systemic medications that would contraindicate lens wear.
  • Any ocular or systemic medical condition that may, in the opinion of the investigator, preclude safe administration of the study lenses or affect the results of this study.
  • History of herpetic keratitis.
  • History of refractive surgery or irregular cornea.
  • History of pathologically dry eye.
  • Corneal vascularization greater than 1 mm of penetration.
  • Eye injury within twelve weeks immediately prior to enrollment in this trial.
  • Participation in a contact lens or contact lens care product clinical trial within the previous 30 days, or concurrent participation in any clinical trial.
  • Other protocol-defined exclusion criteria may apply.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01461811). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search